Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly is demanding healthcare providers to stop promoting and selling off-brand versions of its popular weight loss and diabetes drugs — Zepbound and Mounjaro. The pharma giant has sent ...

Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these companies will ...

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s ... the need for the off-brand versions. “We conclude that the information and data Lilly has provided to ...

"Eli Lilly targets Scorpion Therapeutics to expand reach in oncology" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Let's see if the momentum can continue. While Ozempic has more brand recognition, Eli Lilly's Mounjaro and Zepbound have proven better clinically at helping patients lose weight. The two Eli Lilly ...